Trial · NCT04607772
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1: Maximum Tolerated Dose (MTD) | Within the first cycle (maximum 28 days) of treatment | |
| Primary | Phase 1: Recommended Phase 2 Dose (RP2D) | Up to 6 cycles (up to 6 months) of treatment | |
| Primary | Phase 2: Overall Response Rate (ORR) per the Lugano Classification 2014 | Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) | |
| Secondary | Phase 1: Overall Response Rate per the Lugano Classification 2014 | Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) | |
| Secondary | Phase 1: Disease Control Rate (DCR) per Lugano Classification 2014 | Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR or stable disease (SD) (up to 6 months) | |
| Secondary | Phase 1: Duration of Response (DOR) per Lugano Classification 2014 | Time from the first response of PR or CR until disease progression (up to 12 months) | |
| Secondary | Phase 1: Overall Response Rate (ORR) per the Modified Lugano Classification | Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR (up to 6 months) | |
| Secondary | Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and Severity | From start of study drug administration up to 30 days after last dose of study treatment (up to 24 months) | |
| Secondary | Phase 2: Overall Response Rate per the Modified Lugano Classification | Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a complete response (CR) or partial response (PR) (up to 6 months) | |
| Secondary | Phase 2: Disease Control Rate (DCR) per Lugano Classification 2014 | Cycle 1 Day 1 (each cycle consists of maximum 28 days) until a CR or PR or stable disease (SD) (up to 6 months) | |
| Secondary | Phase 2: Duration of Response (DOR) per Lugano Classification 2014 | Time from the first response of PR or CR until disease progression or death (up to 12 months) | |
| Secondary | Phase 2: Number of Participants With AEs by Occurrence, Nature, and Severity | From start of study drug administration up to 30 days after last dose of study treatment (up to 24 months) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04607772/registered